March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Intravitreal Anti-VEGF Therapy For Retinal Macroaneurysm
Author Affiliations & Notes
  • Sandrine A. Zweifel
    Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland
  • Magdalena Toenz
    Department of Ophthalmology, Cantonal Hospital Lucerne, Lucerne, Switzerland
  • Lukas Pfenninger
    Department of Ophthalmology, Kantonsspital Winterthur, Winterthur, Switzerland
  • Matthias D. Becker
    Department of Ophthalmology, Triemli Hospital Zurich, Zurich, Switzerland
  • Stephan Michels
    Department of Ophthalmology, Triemli Hospital Zurich, Zurich, Switzerland
  • Footnotes
    Commercial Relationships  Sandrine A. Zweifel, None; Magdalena Toenz, None; Lukas Pfenninger, None; Matthias D. Becker, None; Stephan Michels, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 966. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandrine A. Zweifel, Magdalena Toenz, Lukas Pfenninger, Matthias D. Becker, Stephan Michels; Intravitreal Anti-VEGF Therapy For Retinal Macroaneurysm. Invest. Ophthalmol. Vis. Sci. 2012;53(14):966.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effect of intravitreal anti-vascular endothelial growth factor (VEGF) therapy using bevacizumab or ranibizumab for retinal macroaneurysms with macular exudation.

Methods: : In a retrospective interventional case series patients with macroaneurysms were treated with either 1.25mg intravitreal bevacizumab or 0.5mg ranibizumab as first line therapy. Patients were imaged by fluorescein angiography and optical coherence tomography (OCT). Retreatment was performed in case of persistent intraretinal or subretinal fluid in OCT.

Results: : Ten patients (10 eyes) with macroaneurysm involving the macula were treated with an average of 3.0 intravitreal anti-VEGF injections. Mean best corrected visual acuity (BCVA) of all patients improved by 17 letters from baseline to last follow-up visit. In 7 out of 10 patients, the fovea was affected by the secondary edema. In cases with foveal involvement, central retinal thickness decreased from 366µm at baseline to 266µm at last follow-up visit. In the course of treatment 8 out of 10 patients showed evidence of closure of the macroaneurysm.

Conclusions: : Intravitreal anti-VEGF therapy appears to be a promising treatment alternative to laser treatment in cases of retinal macroaneurysms with macular exudation.

Keywords: retina • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • imaging/image analysis: clinical 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.